593 results about "Bacterosira" patented technology

The invention provides isolated polypeptide and nucleic acid sequences derived from Bacteroides fragilis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparation of a composition for treating inflammatory bowel diseases. The experiments show that bacteroides fragilis is safe and nontoxic and strong in pharmacologic action, and has good treating effect of treating inflammatory bowel diseases, thereby indicating that the bacteroides fragilis has good edible and medicinal prospects. According to the invention, a novel use of bacteroides fragilis is explored and a novel application field is developed. Bacteroides fragilis as a probiotic can be used for preparing foods or medical compositions for treating inflammatory bowel diseases so as to provide health-cared foods or treating medicines suitable for human body to take.

The invention relates to a eubacterium biforme preparation. The eubacterium biforme preparation is a microecological preparation adopting eubacterium biforme as a main active ingredient. The invention also relates to a use of the eubacterium biforme preparation in treatment on related diseases. The eubacterium biforme preparation can be prepared into a drug composition, a health care product, a drink, a veterinary drug and a feed additive.

A process of transfecting a plant, comprising spraying parts of said plant with an aqueous suspension containing cells of an Agrobacterium strain and at least one abrasive suspended in said suspension, said Agrobacterium strain comprising a DNA molecule comprising a nucleic acid construct containing a DNA sequence of interest to be transfected into the plant.

The invention discloses bifidobacterium longum and the application thereof and belongs to the technical field of biologics. The invention provides a bifidobacterium longum YS108R strain which has thecharacteristic of generating viscous exopolysaccharide, and has a remarkable improvement function on DSS (Dextran Sulfate Sodium) induced mouse colitis models. The strain has a relatively good capability of enduring simulated gastrointestinal fluids, is capable of remarkably reducing disease activity indexes of mice in the DSS induction period, and has an effective protection function on colon tissue. In addition, the bifidobacterium longum YS108R disclosed by the invention is separated from intestinal florae of healthy people, is free of toxic and / or side effects on human bodies, and has certain advantages when being compared with conventional medicine treatment. The strain can be used for preparing probiotic powder, fermented milk, and the like, and has wide market prospects.

The invention discloses bifidobacterium bifidum capable of remarkably relieving constipation and application thereof and belongs to the technical field of microorganisms. The bifidobacterium bifidum CGMCC NO.13632 can well tolerate simulative gastrointestinal fluid, can be well attached to colon cancer cells HT-29, and can remarkably increase the water content of excrement of constipation mice and shorten the first tarry stool time. On the aspect of increasing the small intestine driving rate, the bifidobacterium bifidum CGMCC NO.13632 is superior to cathartic phenolphthalein, a best effect is shown, secretion of gastrointestinal regulatory peptide relevant to constipation in serum is also adjusted while constipation pathological factors are remarkably improved, and the bifidobacterium bifidum does not have toxic and side effects of medicine for treating constipation, and is a first choice for preventing and treating constipation. The bifidobacterium bifidum CGMCC NO.13632 is used for preparing pharmaceutical compositions and fermented food for relieving constipation, and has very wide application prospects.

The invention discloses a microbial inoculum for decomposing lignocellulose and application thereof. The active component of the microbial inoculum consists of Alcaligenes faecalis, Bacteroides xylanisolvens, Clostridium xylanolyticum, Clostridium lentocellum, Flavobacterium aquatile, and Pseudomonas stutzeri. Experiments prove that the microbial inoculum has high degradation rate to the lignocellulose, and the degradation rate can reach between 60 and 70 percent. The microbial inoculum has low cost and simple preparation, breaks through the limitation that a purification bacterium and a clastic enzyme thereof cannot decompose the lignocellulose efficiently, provides a key technique for decomposing, saccharifying biomass containing cellulose and converting the biomass into an energy source, and has extensive application prospect in the field of decomposing the lignocellulose.

The invention relates to acinetobacter calcoaceticus X.L.Zhu.SGD07-3-16 with free living nitrogen fixation capability. The acinetobacter calcoaceticus is preserved in China general microbiological culture collection center, and the preservation number of the acinetobacter calcoaceticus is CGMCCNo.5455. The acinetobacter calcoaceticus is high in nitrogenase activity and phosphorus and potassium dissolving capability, and has ACC (1-aminocyclopropane-1-carboxylic acid) deaminase activity, a certain amount of indoleacetic acid can be generated, and the generation of siderophore is avoided; when an acinetobacter calcoaceticus-containing liquid or solid microbial agent is used for inoculating crops such as corns, oilseed rapes and leaf mustard, the growth of the crops can be remarkably promoted, and the yield of the crops can be increased.

Antibacterial compositions effective against both gram positive and gram negative vegetative bacteria plus harmful gram positive sporeforming bacteria include propionibacterial metabolites in combination with two or more of the following: a lantibiotic; a lytic enzyme; and an organic acid or its salt. Methods of use are provided, as well as food products treated with these antibacterial compositions.

The invention relates to a recombinant corynebacterium crenatum to enhance the expression of N-acetyl glutamic acid kinase and the application thereof, which belongs to the technical field of gene engineering. The classification and nomenclature of the recombinant corynebacterium crenatum to enhance the expression of N-acetyl glutamic acid kinase is corynebacterium crenatum SYPA / pJC1-tac-argB with an access number of CCTCC NO: M 208133; The application is as follows: using a key enzyme N-acetyl glutamic acid kinase from corynebacterium crenatum pathway arginine to construct a corynebacterium crenatum expression vector pJC1-tac-argB; introducing the corynebacterium crenatum expression vector pJC1-tac-argB into corynebacterium crenatum SYPA by electrotransformation to obtain the recombinant corynebacterium crenatum SYPA / pJC1-tac-argB; and excessively expressing N-acetyl glutamic acid kinase, which greatly enhances the utilization rate of a precursor glutamic acid and allows the metabolic flow to flow to the arginine synthesis pathway, weakens the synthesis of proline, achieves the purpose of improving the output of arginine and the output of arginine is increased by 23.4 percent than C. crenatum SYPA.

An infant and / or toddler nutrition comprising non-viable Bifidobacterium breve and a non-digestible oligosaccharide and its use are disclosed.

The invention relates to a preparation method of bacteroides fragilis capsular polysaccharide A. The preparation method comprises the following steps: preparing a bacterial suspension of bacteroides fragilis with the pH value of less than or equal to 5, heating and extracting, and collecting an extracting solution to obtain a crude sugar solution of capsular polysaccharide A. Compared with the prior art, the preparation method has the following beneficial effects that the inventor accidentally finds that the capsular polysaccharide A can be effectively promoted to fall off from the bacteroides fragilis thalli by heating and extracting the bacteroides fragilis bacterial suspension of which the pH value is less than or equal to 5, so that the capsular polysaccharide A is extracted. Compared with a traditional phenol / water method, the capsular polysaccharide A can be obtained under the condition that phenol is not used, and the toxicity is low. Moreover, by adopting the preparation method, the yield of the bacteroides fragilis capsular polysaccharide A is obviously improved.

The invention discloses a novel Bifidobacterium breve with excellent probiotic function. The Bifidobacterium breve strains are obtained by screening the feces of the long-lived elders in Hetian, XinJiang, and the obtained strains have outstanding resistance to acid and bile acid salts, adhesion characteristics to intestinal tract epidermic cells, excellent antibacterial performance and good oxidization resistance; and the strains have an effect on reducing the blood pressure as well as the edible safety, therefore, the Bifidobacterium breve can be widely applied in the fields such as functional additives, dairy products, beverage, functional food, drug production, etc.

The invention discloses a cosmetic with fermented original rice milk, a method for manufacturing the cosmetic and application thereof. A process for preparing the fermented original rice milk includes steps of fermenting and cultivating initial systems with bifidobacterium bifidum, dry rice flour and water to obtain the fermented original rice milk. A bacterium is the bifidobacterium bifidum. As proved by experiments, the cosmetic, the method and the application have the advantages that the fermented original rice milk does not contain optional chemical components, accordingly, the cosmetic can be directly used as a finished product of facial masks or essence or toner and is natural as compared with other products on current markets, and optional negative effects on the skins of users can be prevented; small components can be acquired by the aid of the method as compared with common extraction methods, and accordingly the cosmetic can be easily sufficiently absorbed by the skins of the users.

The invention provides a method for producing L-ornithine by microbial fermentation, namely, using Corynebacterium glutamate to obtain the strains of CS-189(cit<(-)>+SG<r>) by chemical treatment, and obtain the L-ornithine hydrochloride by fermentation, culture solution micro-filtration by a ceramic membrane, ion exchange resin and extraction by a hydrothermal crystallization method with decompression concentration. The strains used in the method are auxotrophy resistant to sulfaguanidine, which significantly enhances acid yield by fermentation. Meanwhile, aiming at the problem that the solubility of the L-ornithine hydrochloride in water is extremely difficult, the hydrothermal crystallization method is adopted to obtain better extraction rate under the condition that flammable and explosive alcohol is not used. The method simplifies processes and reduces extraction cost.

The invention relates to the use, in the manufacture of a medicament or a therapeutic nutritional composition for preventing or reducing inflammation in a mammal, of bifidobacterium longum ATCC BAA-999.

The present invention relates to nucleic acid and amino acid sequences from Akkermansia muciniphila and from Bacteroides fragilis, coding for / representing novel alpha-1,3-fucosyltransferases. The invention also provides uses and methods for using the alpha-1,3-fucosyltransferases to generate fucosylated products, such as oligosaccharides, (glyco)proteins, or (glyco)lipids, in particular of 3-fucosyllactose.

Antimicrobial compositions for oral delivery, and administration to the colon, distal ileum, or other portion of the gastrointestinal tract other than the stomach, of bacteriophage, phage proteins, antimicrobial peptides, or antimicrobial aptamers, are disclosed. In one embodiment, the active agent is capable of lysing the bacterial cell wall. In another embodiment, the active agent is capable of interacting with a receptor or enzyme in the bacteria. In some embodiments, the active agents selectively act on one or more harmful bacteria, such as Clostridium difficile, and either do not act, or act to a lesser extent, on helpful bacteria, such as bifidobacteria. When the agents are not delivered directly to the colon, they active agents ultimately enter the colon and affect the bacteria that are present in the colon. The compositions can include beads of pectin in the form of a cationic salt enclosing the active agent, or other types of drug delivery systems designed for targeted delivery to the desired portion of the gastrointestinal tract.

The invention discloses an air filter type bacterial cellulose mask and a production method thereof. The mask is made of dried bacterial cellulose which is used as a mask frame material. The preparation method comprises the following steps: selecting acetobacter xylinum as a type strain, and culturing the acetobacter xylinum to obtain a bacterial cellulose membrane; and after soaking the membrane in acid liquor and alkali liquor, washing the soaked membrane till the rate of impurities is less than 0.5 percent, soaking the membrane in nano-silver solution, then drying the membrane by adopting a freeze drying mode, and obtaining the air filter type bacterial cellulose mask through compound preparation. The preparation process is simple, the filter performance of the mask can be effectively improved by using the bacterial cellulose as a material, and the bactericidal and antitoxic capacities of the mask are enhanced by soaking in the nano-silver solution; and the mask has the characteristics of low production cost, strong adsorption capacity, high bactericidal activity, long durative bactericidal time and the like, and can effectively reduce resource consumption and protect ecological environment.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparing a composition for preventing and treating acute radiation enteritis. Experiments show that bacteroides fragilis is safe, nontoxic and strong in pharmacologic action and has a good preventing and treating effect to acute radiation enteritis, thereby indicating that the bacteroides fragilis has good edible and officinal prospects. The invention explores novel use of bacteroides fragilis and develops a novel application field. Bacteroides fragilis serving as probiotic can be used for preparing foods or medical compositions for preventing and treating acute radiation enteritis.

The invention discloses a kelp-flavored food ingredient and a preparation method thereof. The preparation method comprises the following steps: firstly, degrading effective ingredients of kelp by composite enzymes; secondly, fermenting kelp enzymolysis products by corynebacterium glutamicum and pediococcus pentosaceus mixed bacteria; thirdly, further degrading the effective ingredients of the kelp and releasing secondary metabolites with functionality; fourthly, carrying drying or spray drying on fermented products to obtain a kelp food with rich kelp flavor, easily absorbed nutrients, antioxidant activity and antibacterial activity, so that the added value of a product is increased. According to the preparation method, a conventional deep processing process of the kelp is broken through, a composite enzymatic hydrolysis process is organically combined with a food grade microorganism fermentation process, the shortcomings of low utilization rate, unremarkable product flavor, non-effective utilization of the nutrients, poor functionality and the like in the conventional deep processing process of the kelp are overcome, the application range of the kelp product is remarkably expanded, and the economic value of the kelp product is remarkably increased.

The invention discloses a gluconoacetobacter sp. strain and a screening and purifying method. The screening and purifying method is characterized in that: defective fruits are used as raw materials; cycloheximide is used to suppress the growth of molds and other fungi, and plate enrichment cultivation, gradient dilution plate coating, primary screening, second screening and other methods are adopted for screening and purification to obtain the strain generating bacteria cellulose. According to the description in the ninth version of Bergey's Manual of Determinative Bacteriology, the strain is determined as a novel strain by the analysis of physiological and biochemical properties and 16 Sr DNA sequence. The invention strain obtained by the method has a wide selection range of carbon sources and nitrogen sources, a maximum yield of bacteria cellulose at a pH value of 6.5 and normal temperature, and a higher yield than that of common cellulose-generating bacteria, and has better implementation prospect in the industrial production of bacteria cellulose.

The invention provides a method of producing tetrahydropyrimidine by fermenting recombinant corynebacterium glutamicum. The recombinant corynebacterium glutamicum is obtained by the steps of performing overexpression in corynebacterium glutamicum to relieve an aspartokinase gene lysC of feedback inhibition; then replacing a promoter of a dihydropyrimidine dicarboxylic acid synthetase in the recombinant bacteria to weaken the activity of the dihydropyrimidine dicarboxylic acid synthetase; and then transferring tetrahydropyrimidine synthetic path related gene ectABC into the recombinant bacteria to obtain the recombinant corynebacterium glutamicum. The recombinant corynebacterium glutamicum provided by the invention can use different cheap raw materials to produce tetrahydropyrimidine by fermentation under a low salt condition, and cheap corn slurry can be also used as a nutritional component which replaces expensive yeast powder, so that the cost of the raw materials is further lowered. Meanwhile, the recombinant corynebacterium glutamicum provided by the invention solves the problem of biosafety, simplifies the post-extraction process and has a good market application prospect.

The invention discloses bifidobacterium animalis NX-6 and application thereof in preparation of lipid-lowering and weight-losing medicines, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium animalis NX-6 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 20114. The uninactivated and inactivated fermentation supernate, bacterial suspension and cell disrupted supernate of novel bifidobacterium animalis NX-6 show good effects of slowing down weight and body length increase, improving body mass index(BMI) and reducing fat area percentage on zebrafish, and have a potential weight losing effect; triglyceride (TG) and total cholesterol (TC) in a zebrafish hyperlipidemia model body can be obviously reduced, and a good hypolipidemic effect is shown. The novel bifidobacterium animalis NX-6 disclosed by the invention has a huge potential application prospect in the aspect of preparing medicines fortreating and / or preventing obesity and hyperlipidemia.

The invention provides a bifidobacterium bifidum lyophilization composite protection agent and application method thereof. A formula of the bifidobacterium bifidum lyophilization composite protection agent is composed of xylooligosaccharide of 3.0 to 5.0 g, synanthrin of 6.0 to 8.0 g, stachyose of 5.0 to 7.0 g, glycine 2.0 to 4.0 g, arginine of 2.0 to 4.0 g, sodium bicarbonate of 0.4 to 0.6 g andsodium ascorbate of 0.7 to1.2 g. the composite protection agent is utilized to lyophilize bifidobacterium bifidum, lyophilization survival reaches more than 85%, and viable count of bacterium powder is larger than 2.0 * 1011 cfu / g. Prebiotic of the xylooligosaccharide, synanthrin and stachyose is added in the composite protection agent so as to further improving a health protection function of the bacterium powder of the bifidobacterium bifidum. The composite protection agent resolves the important key technology problems in processes of develop high activity bacterium powder of the bifidobacterium bifidum. The prepared high activity bacterium powder can serve as addition agents and leavening agents to be used for developing functionality food and pharmaceutical preparation of the bifidobacterium bifidum.

The invention relates to the technical field of bioengineering, in particular to recombinant corynebacterium glutamicum and a method for producing L-threonine. The corynebacterium glutamicum for producing threonine is constructed by combining and transforming (or enhancing) a hom gene, a lysC gene, a thrC gene and the like which are resistant to feedback inhibition, and (or) a weakening (or knockout) pck gene and (or) a weakening (or knockout) pyk gene, and the acid production effect is very remarkable and far exceeds the highest level which is reported at present and reaches 20g / l.

The invention discloses recombinant corynebacterium glutamicum for producing gamma-polyglutamic acid as well as a construction method and a use of the recombinant corynebacterium glutamicum. The recombinant corynebacterium glutamicum is characterized by being an engineering bacteria which is obtained by transferring a recombinant expression plasmid containing a gamma-PGA (Poly Glutamic Acid) synthetase composite gene pgsBCA to an original strain wild C.glutamicum ATCC13869. The recombinant corynebacterium glutamicum disclosed by the invention contains the gamma-PGA synthetase composite gene pgsBCA, so that much gamma-PGA can be synthesized under biotin limit or under the fermentation condition of adding Tween40, therefore, the glutamic acid adding cost in the gamma-PGA production process is reduced, and a foundation is laid for the innovation in realizing the one-step production of gamma-PGA better.

This invention relates to novel probiotic Bifidobacteria strains, particularly, a B. pseudocatenulatum strain, and its use as probiotic, and food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of obesity, diabetes (particularly Type 2 diabetes), and related conditions.

A probiotic coated kibble having internal glycerin.

The invention discloses a carbonyl reductase (i)Ch ( / i) KRED15 derived from Chryseobacterium ((i) Chryseobacterium ( / i) (i) ( / i) sp. CA49), and a coding gene thereof; the invention also discloses application of the carbonyl reductase as a biocatalyst in preparing a Duloxetine chiral intermediate ((i) S ( / i))-N-methyl-3-hydroxy-3-(2-thienyl) propanamide. The enantiomer excess of products is greater than 99.9%. 20 g / L of substrate can be catalyzed by Ch( / i) KRED15 crude enzyme (2U / mL), and the conversion rate of over 99% can be obtained in 2 hours; a coenzyme circulation system is simple, and has large industrial application prospect.